Intended for healthcare professionals


Biotechnology company's shares dive 67% after drug failure

BMJ 2000; 321 doi: (Published 28 October 2000) Cite this as: BMJ 2000;321:1039
  1. Roger Dobson
  1. Abergavenny

    The United Kingdom's emerging biotechnology industry has suffered another bruising, with the share price of Cantab Pharmaceuticals plunging 67% after trials found that its treatment for recurring genital warts was no better than placebo.

    A month earlier, shares in Scotia Holdings fell by 60% after it failed to get US regulatory approval for its leading drug for cancer. Last year in the wake of the first results from a programme of 10 randomised controlled trials of Marimastat, British Biotech's share price fell to an all time low.

    According to the industry, these huge falls …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription